Ticker > Company >

Venus Remedies share price

Venus Remedies Ltd.

NSE: VENUSREM BSE: 526953 SECTOR: Pharmaceuticals & Drugs  43.35 K   74   6

480.30
0 0
NSE: Today, 09:34 AM

Price Summary

Today's High

₹ 0

Today's Low

₹ 0

52 Week High

₹ 567.8

52 Week Low

₹ 270.25

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

642.02 Cr.

Enterprise Value

564.03 Cr.

No. of Shares

1.34 Cr.

P/E

10.73

P/B

1.07

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  449.75

CASH

77.99 Cr.

DEBT

0 Cr.

Promoter Holding

41.76 %

EPS (TTM)

₹  44.75

Sales Growth

11.17%

ROE

9.57 %

ROCE

13.91%

Profit Growth

72.34 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.17%
3 Year3.5%
5 Year14.83%

Profit Growth

1 Year72.34%
3 Year2.38%
5 Year53.02%

ROE%

1 Year9.57%
3 Year7.33%
5 Year9.77%

ROCE %

1 Year13.91%
3 Year10.24%
5 Year10.21%

Debt/Equity

0

Price to Cash Flow

7.73

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

1.48581498845031

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 41.76 0.00
Mar 2025 41.76 0.00
Dec 2024 41.76 0.00
Sep 2024 41.76 0.00
Jun 2024 41.76 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 38.6789 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.148369026242516.
  • The company has an efficient Cash Conversion Cycle of 57.5855 days.
  • Company has a healthy liquidity position with current ratio of 4.1408.
  • The company has a good cash flow management; CFO/PAT stands at 1.48581498845031.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.30074822291574.

 Limitations

  • The company has shown a poor profit growth of 2.37685292628702% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.5027292382787% for the Past 3 years.
  • Company has a poor ROE of 7.3341% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 105.86 167.02 172.54 194.04 131.85
Total Expenditure 91.58 156.75 149.63 171.49 119.2
Operating Profit 14.28 10.27 22.91 22.55 12.65
Other Income 1.56 10.71 1.74 6.77 8
Interest 0 0 0 0 0
Depreciation 5.76 6.17 5.2 4.49 5.95
Exceptional Items 0 0 9.91 0 0
Profit Before Tax 10.08 14.81 29.36 24.83 14.7
Tax 5.63 5.55 5.28 10.04 3.01
Profit After Tax 4.45 9.26 24.08 14.79 11.69
Adjusted EPS (Rs) 3.33 6.93 18.01 11.06 8.74

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 514.62 576.71 537.66 575.21 639.46
Total Expenditure 467.76 507.89 476.14 514.32 569.47
Operating Profit 46.86 68.82 61.53 60.89 70
Other Income 17.76 8.43 10.17 11.32 20.78
Interest 12.73 0 0 0 0
Depreciation 34.28 32.58 31.37 25.55 21.62
Exceptional Items 23.44 0 0 0 9.91
Profit Before Tax 41.06 44.67 40.33 46.65 79.08
Tax -13.21 -4.32 11.36 16.15 26.51
Net Profit 54.27 48.99 28.96 30.5 52.56
Adjusted EPS (Rs.) 43.97 36.65 21.67 22.82 39.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 12.34 13.37 13.37 13.37 13.37
Total Reserves 387.84 436.05 464.68 495.22 576.13
Borrowings 47.52 38.68 38.68 38.68 0
Other N/C liabilities 11.29 7.27 19.49 21.18 18.48
Current liabilities 87.82 82.61 72.67 72.81 105.23
Total Liabilities 546.81 577.98 608.89 641.26 713.21
Assets
Net Block 244.2 224.67 199.68 202.76 214.14
Capital WIP 25.11 25.23 26.1 21.08 26.39
Intangible WIP 0 0 0 0 0
Investments 0.14 0.14 0.14 0.16 0.16
Loans & Advances 62.34 61.96 62.55 51.76 33.56
Other N/C Assets 1.29 1.57 2.23 4.5 3.21
Current Assets 213.74 264.41 318.19 361 435.75
Total Assets 546.81 577.98 608.89 641.26 713.21
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 17.62 44.67 40.33 46.65 69.16
Adjustment 21.59 24.83 22.25 19.36 14.01
Changes in Assets & Liabilities 69.69 -28.5 -34.53 -15.15 14.86
Tax Paid 0 0 0 -15.48 -14.92
Operating Cash Flow 132.34 41 28.05 35.38 83.1
Investing Cash Flow 55.98 -16.75 -50.81 -6.94 -76.2
Financing Cash Flow -161.88 -9.13 0 0 0
Net Cash Flow 26.45 15.12 -22.76 28.44 6.9

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 41.76 41.76 41.76 41.76 41.76
manu chaudhary 11.73 11.73 11.73 11.73 11.73
pawan chaudhary 12.82 12.82 12.82 12.82 12.82
sunev pharma solutions li... 17.21 17.21 17.21 17.21 17.21
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 58.24 58.24 58.24 58.24 58.24
acadian emerging markets ... 1.05 1.10 1.10 1.10 1.10
anurag jain - - - 1.12 1.12
investor education and pr... - 1.00 1.00 1.00 1.00
k.b.shekar 1.97 1.97 1.97 1.97 1.94
llp 0.39 0.12 0.20 0.20 0.23
rajni tarun jain - - - 1.50 1.50
pradeep kumar jain 1.87 2.00 2.12 2.78 -
mc jain infoservices priv... 1.50 2.32 2.32 - -
investor education and pr... 1.00 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies informs about confirmation certificate 8 Jul, 12:20 PM Venus Remedies - Quaterly Results 26 May, 10:29 PM Venus Remedies - Quaterly Results 26 May, 10:29 PM Venus Remedies secures Ukrainian GMP renewal 22 May, 2:30 PM USFDA grants QIDP Designation to Venus Remedies’ investigational product VRP-034 17 Apr, 12:59 PM Venus Remedies sings license agreement with lnfex Therapeutics to develop MET-X 25 Feb, 12:43 PM Venus Remedies informs about press release 25 Feb, 10:27 AM Venus Remedies - Quaterly Results 4 Feb, 9:02 PM Venus Remedies - Quaterly Results 4 Feb, 9:02 PM Venus Remedies gets GMP certification for antibiotic-carbapenem facility 31 Dec, 2:45 PM Venus Remedies secures Marketing Authorization in Philippines 6 Dec, 3:51 PM Venus Remedies gets nod to establish wholly owned subsidiary in Hungary 30 Nov, 3:17 PM Venus Remedies informs about press release 5 Nov, 11:37 AM Venus Remedies secures Malaysian PIC/S GMP approval for pre-filled syringe facility 5 Nov, 10:44 AM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies informs about closure of trading window 24 Sep, 5:27 PM Venus Remedies - Quaterly Results 13 Aug, 7:28 PM Venus Remedies informs about postponement of board meeting 17 Jul, 10:16 AM Venus Remedies informs about closure of trading window 26 Jun, 10:05 AM Venus Remedies gets oncology tender from PAHO 19 Jun, 10:50 AM Venus Remedies informs about updates 13 Jun, 12:21 PM Venus Remedies secures award for antibiotic product Ceftriaxone 1gm from UNICEF 13 Jun, 9:50 AM Venus Remedies informs about newspaper publication 1 Jun, 3:03 PM Venus Remedies - Quaterly Results 30 May, 8:54 PM Venus Remedies informs about disclosure 1 Apr, 12:58 PM Venus Remedies gets marketing authorisations from Ukraine for three cancer drugs 18 Mar, 4:47 PM Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine 9 Mar, 3:39 PM Venus Remedies awarded first incentive of Rs 7.50 crore under PLI scheme 6 Mar, 10:30 AM Venus Remedies informs about press release 6 Mar, 9:33 AM Venus Remedies - Quaterly Results 14 Feb, 8:01 PM Venus Remedies - Quaterly Results 14 Feb, 8:01 PM Venus Remedies secures marketing authorizations for Docetaxel, Gemcitabine in Europe 12 Jan, 12:30 PM Venus Remedies secures marketing authorizations for Docetaxel in Israel, Cytarabine in Colombia 21 Dec, 3:13 PM Venus Remedies’ R3SET forays into wellness arena 20 Dec, 2:10 PM Venus Remedies informs about press release 20 Dec, 12:56 PM Venus Remedies informs about disclosure 5 Dec, 12:16 PM Venus Remedies gets market authorizations for Enoxaparin in Azerbaijan 5 Dec, 11:09 AM Venus Remedies informs about press release 1 Dec, 2:06 PM Venus Remedies informs about unaudited financial results 25 Nov, 3:19 PM Venus Remedies informs about press release 6 Nov, 10:23 AM Venus Remedies secures ‘Three Star Export House’ certificate from Government of India 6 Nov, 9:49 AM Venus Remedies informs about press release 1 Nov, 10:45 AM Venus Remedies wins FICCI Healthcare Award 2023 1 Nov, 9:52 AM Venus Remedies achieves market authorization for Bleomycin in United Kingdom 26 Oct, 12:07 PM Venus Remedies informs about press release 26 Oct, 10:38 AM Venus Remedies informs about press release 20 Oct, 11:24 AM

Venus Remedies Stock Price Analysis and Quick Research Report. Is Venus Remedies an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Venus Remedies and its performance over the period of time. Venus Remedies stock price today is Rs 480.3.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Venus Remedies cash from the operating activity was Rs 83.1029 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Venus Remedies has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Venus Remedies , the EPS growth was 72.3364 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Venus Remedies has OPM of 10.9464540364058 % which is a bad sign for profitability.
     
  • ROE: Venus Remedies have a poor ROE of 9.5736 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Venus Remedies is Rs 480.3. One can use valuation calculators of ticker to know if Venus Remedies share price is undervalued or overvalued.
Last Updated on:
Brief about Venus Remedies
X